Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Medtronic
McKinsey
Express Scripts
Mallinckrodt

Last Updated: February 25, 2020

DrugPatentWatch Database Preview

Patent: 10,144,777

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,144,777
Title:B-lymphocyte targeting agents for use in a method for the treatment of a disease
Abstract: The present invention is related to a B-lymphocyte targeting agent for use in a method for the treatment or diagnosis of cardiac insufficiency. Furthermore, it is related to a composition comprising such B-lymphocyte targeting agent and methods for determining whether a patient suffering from cardiac insufficiency is amenable to the use of the B-lymphocyte targeting agent for its treatment.
Inventor(s): Tschope; Carsten (Berlin, DE), Schultheiss; H. P. (Berlin, DE), Escher; Felicitas (Berlin, DE), Volk; Hans-Dieter (Berlin, DE), Reinke; Petra (Berlin, DE)
Assignee: Charite--Universitatsmedizin Berlin (Berlin, DE)
Application Number:13/264,090
Patent Claims:see list of patent claims

Details for Patent 10,144,777

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Charite--Universitatsmedizin Berlin (Berlin, DE) 2029-04-16 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Charite--Universitatsmedizin Berlin (Berlin, DE) 2029-04-16 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Charite--Universitatsmedizin Berlin (Berlin, DE) 2029-04-16 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Charite--Universitatsmedizin Berlin (Berlin, DE) 2029-04-16 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
McKinsey
McKesson
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.